Marriott CEO Sorenson dead at 62 after pancreatic cancer battle

Sorenson, 62, temporarily reduced his schedule earlier this month due to 'more demanding treatment for pancreatic cancer.'

Marriott International CEO Arne Sorenson died Monday after a battle with pancreatic cancer, the company said in a statement Tuesday.

Sorenson, 62, temporarily reduced his schedule earlier this month due to "more demanding" cancer treatment. He was first diagnosed with cancer in May 2019.

Ticker Security Last Change Change %
MAR MARRIOTT INTERNATIONAL INC. 281.45 +2.67 +0.96%

He became the CEO of the hospitality company in 2012, the first not bearing the Marriott surname, and helmed the company through its acquisition of Starwood Hotels and Resorts. Sorenson had been with the company since 1996.

READ: MARRIOTT CEO SORENSON REDUCED HIS SCHEDULE FOR CANCER TREATMENT

“Arne was an exceptional executive – but more than that – he was an exceptional human being,” said Marriott Executive Chairman J.W. Marriott, Jr.

Marriott is expected to name a new CEO in the coming weeks. The companies operations are currently being overseen by Marriott executives Stephanie Linnartz and Tony Capuano, who were tapped to head up the responsibilities when Sorenson stepped back from his day-to-day duties earlier this month.

CLICK HERE TO GET FOX BUSINESS ON-THE-GO

Sorensen first announced that he would be “temporarily reducing his schedule” in a statement issued Feb. 2, to undergo “more demanding" cancer treatment. At the time, he was expected to step back for several months.

“Since my diagnosis, I’ve been working with a great medical team at Johns Hopkins to treat this cancer,” Sorenson said. “While I have worked throughout my treatment to date and plan to remain as engaged in the business as my health allows, the right thing for me, my family and the company is to focus on my health. I know Stephanie and Tony will work with Marriott’s strong executive to continue to move the company forward. I, alone with my family and my medical team, remain optimistic about my prognosis and I plan to return full-time after the conclusion of my treatments.”

Alexandria Hein contributed to this report.

Load more..